Despite significant advancements made in life expectancy over the past century, cystic fibrosis remains a life-threatening genetic disease that affects the gastrointestinal tract, and it has significant impact on the nutrition status of those with the disease. Nutrition management includes a high-calorie/high-fat diet, pancreatic enzyme replacement therapy, vitamin and mineral replacement, and enteral support as needed. As patients are living longer, clinicians may encounter patients with cystic fibrosis in obstetrician offices, endocrine clinics, or hospital settings, owing to lung transplantation or for treatment for distal intestinal obstruction syndrome. (Nutr Clin Pract.
Background
Cystic fibrosis (CF) is a life-shortening autosomal recessive genetic disorder that is the result of a defect in the CF transmembrane conductance regulator (CFTR) on chromosome 7. 1 This genetic defect results in defective transport of chloride across the cell membrane, leading to thick mucus secretions in the respiratory, digestive, and reproductive tracts. It also leads to excessive losses of sodium and chloride in sweat.
Manifestations of the disease often include frequent respiratory infections resulting in progressive scarring of lung tissue, impaired absorption resulting in suboptimal weight gain and growth, and impaired fertility.
Advancements in therapies have led to significant improvements in life expectancy over the past century. When CF was first recognized as a clinical entity in 1938 by Dorothy Andersen, most died in infancy from malnutrition. 2 Life expectancy now has reached mid-to late 30s owing to advancements in nutrition and respiratory treatments.
Among these advancements was the discovery of the CF gene in 1989. Since then, >1500 mutations of CFTR have been identified, which can cause various symptoms of ranging severity-from absence of the vas deferens (leading to infertility in males) to pancreatic insufficiency (PI) and progressive bronchiectasis. 3 About 50% of patients with CF carry 2 copies of the delta F508 mutation, and almost 90% of patients carry 1 copy of the mutation. 3 This mutation is associated with PI, particularly when a patient carries 2 copies of the gene. All 50 states now conduct newborn screening within the first 2-3 days of life, and the majority of cases of CF are now diagnosed within the first month of life.
Approximately 28,000 people with CF in the United States are part of the Cystic Fibrosis Foundation (CFF) patient registry; more than half are now adults. 4 There are 110 care centers across the United States that offer multidisciplinary specialty care to those affected with CF; team members include physicians, dietitians, social workers, nurses, and respiratory and/or physical therapists. Patients are followed quarterly, and routine care guidelines generally involve pulmonary function testing, measurement of weight and height/length, respiratory cultures, annual laboratory work, and at least annual assessments by multidisciplinary team members. 4 In 2013, the first CFTR potentiator drug (VX-770, also known as ivacaftor) became available on the market to treat patients aged 6 years who carry the G551D mutation (approximately 4% of the CF population). 4, 5 Ivacaftor has shown great promise in the CF community, leading to significant improvements in pulmonary function, weight, and CFTR activity as compared with placebo for those who carry the 591604N CPXXX10.1177/0884533615591604Nutrition in Clinical PracticeSchindler et al
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From 1 G551D mutation, and it offers much hope for other CFTR potentiator drugs currently being studied for more common mutations, such as delta F508. 4 
Nutrition and CF
Malnutrition was once thought of as an inevitable consequence of CF. Older pancreatic enzyme preparations were not enteric coated; as a result, much of the active enzyme was destroyed by gastric acid, leading to symptoms of steatorrhea whenever patients with CF consumed fat in their diet. A low-fat diet was recommended for many years as a way to control symptoms; however, severe malnutrition was a consequence of inadequate caloric intake, and poor growth was common. The evolution of enteric-coated enzymes in the 1970s and the results of a hallmark study in the 1980s-which showed that a high-fat diet led to improved nutrition status and longer survival-changed the nutrition management of CF. 6 Today, achieving and maintaining optimal nutrition status is viewed as a critical component of CF care. Indeed, research continues to support the important role of optimal nutrition status in improving clinical outcomes in CF. Yen et al showed an association between patients who had a greater weight at age 4 and greater height, better pulmonary function, fewer complications of CF, and better survival through age 18 years. 7 An analysis of the European CF patient registry indicated that CF patients with a lower body mass index (BMI) experience a sixfold-increased odds ratio of having severe lung disease as compared with patients with normal BMI. 8 As a result of more focus and attention toward improving nutrition outcomes in individuals with CF, improvements in weight and height percentiles have been noted over the past 3 decades; however, they have not yet achieved growth rates seen in healthy children without CF in the United States. 4 Evidence-based nutrition goals based on age and sex for individuals with CF, based on U.S. CFF registry data analysis, are as follows 9 :
Birth-24 months: 50th-percentile weight/length (Centers for Disease Control and Prevention growth chart) 2-20 years: 50th-percentile BMI (Centers for Disease Control and Prevention growth chart) 20 years: women-BMI, 22; men-BMI, 23
Estimating energy needs can be complicated, and it is important to monitor weight gain to gauge response to nutrition interventions. Presence and degree of malabsorption (which can be difficult to quantify), sex, degree of pulmonary involvement, and secondary complications (eg, liver disease) can affect energy needs. 10, 11 Ranges of 110%-200% of that of individuals without CF have been recommended by various sources. 9, 12 Infants with CF should receive human milk, similar to what is recommended for all healthy, full-term infants, to receive the benefits associated with breast milk feedings and possibly other benefits specific to infants with CF. 13 If human milk is not available, standard infant formula is an appropriate choice; enzyme replacement therapy is necessary for all infants with PI regardless of the type of feeding chosen. 13 Feedings, enzyme replacement therapy, and vitamin/mineral therapy should be managed by a CF center or in conjunction with a CF care team who will eventually be managing the infant if he or she is temporarily managed at an outside facility.
Once on solid foods, most individuals with CF are managed with a high-calorie diet, composed of a high-fat intake (35%-40% of energy needs) to help make it easier to meet the highcalorie demand.
14 In general, patients who take in adequate calories also consume adequate protein. 12 Healthy eating behaviors and positive meal-time environments should be encouraged from a young age, since problematic eating behaviors, such as picky and slow eating, have been described in the literature. 15 Promoting the use of high-calorie, high-fat additives to foods and beverages-such as oils/butter, cheese, nut butters, and avocado-can help meet high-energy demands without putting additional burden of increasing volume of food needing to be consumed by the patient.
Pancreatic Insufficiency
PI is the primary cause of malabsorption in individuals with CF; CFTR dysfunction at the apical surface of epithelial cells of pancreatic ducts results in ductal plugging, obstruction, and progressive damage to the pancreas. 16, 17 Nutrient malabsorption does not occur until only 1%-2% of residual capacity of pancreatic enzyme secretion remains, known as PI. 16, 17 Pancreatic disease develops in utero as evidenced by the presence of PI in infancy. 16 However, some patients with CF are not diagnosed as having PI until they are toddlers and, in a few cases, not until they are adults. There are close associations between pancreatic phenotype-PI or pancreatic sufficient (PS)-and genotype, with mild CFTR mutations more likely to result in PS. 16, 17 Eighty to ninety percent of patients with CF require pancreatic enzyme replacement therapy (PERT). 18 Subjective symptoms of maldigestion secondary to PI can include frequent stooling, steatorrhea (large, oily, malodorous stools), excess flatus, abdominal bloating, abdominal pain, and yellow-or clay-colored stools that may or may not float but do often fall apart or are not formed at all. 16, 19 Patients may have trouble gaining weight despite a voracious appetite. However, since these symptoms can mimic many other gastrointestinal disturbances, pancreatic function should always be confirmed using diagnostic tools.
Two noninvasive tests can confirm PI. The fecal elastase 1 test is a qualitative study that requires a small stool sample and is therefore easily obtained. Fecal elastase 1 is not affected by exogenous enzymes, so patients can be taking enzyme products at the time that the stool is collected for study. 19, 20 Fecal elastase 1 values <200 µg/g show PI. 18 Loose, watery stools may result in a false positive, so it is important to repeat the test to confirm results, especially if the stools were loose at the time of testing. 19, 20 A 72-hour fecal fat study can be used as a quantitative measure of absorption; since it is more cumbersome, it is generally used only to determine effectiveness of PERT. 19 PI results in poor digestion and absorption of macronutrients (ie, fat, protein, and carbohydrate) and fat-soluble vitamins A, D, E, and K . The goal of treating PI is to optimize nutrient absorption, resulting in improved weight gain and growth, and to prevent nutrient deficiencies. Pancrelipase products consist of a mixture of porcine lipase, protease, and amylase. Most products are enteric-coated microspheres or microtablets contained within a gelatin capsule. The enteric coating protects the enzymes from gastric acid degradation, ideally being activated within the duodenum in an alkaline environment (pH >5.0-5.5). 19 Enzymes can be dosed on the basis of a patient's weight and/or fat intake; see Table 1 for dosing and administration guidelines. Evaluating response to enzymes should be a routine part of the nutrition assessment, which includes monitoring for bulky, oily, light-colored stools; symptoms of gastrointestinal discomfort (including excessive flatus and/or abdominal pain); and weight gain in the context of caloric intake. 17 Many factors may contribute to suboptimal response, including lack of adherence, a "grazing" eating pattern (making enzyme dosing more difficult), and physiologic abnormalities such as hyperacidity of the small bowel or delayed gastric emptying. 17 Medications to decrease acid production, such as H2 antagonist or proton pump inhibitor, are often used as adjunctive therapy to alkalinize the proximal small intestine and increase enzyme efficacy.
17 Table 2 contains current enzyme preparations on the market in the United States.
Adverse side effects of PERT are rare, but fibrosing colonopathy, resulting in colonic strictures, is associated with ingestion of large quantities of PERT (>6000 lipase units per kilogram per meal for >6 months).
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Vitamins and Minerals
Prior to the widespread use of newborn screening to diagnose CF, symptoms of overt vitamin and mineral deficiencies often were initial signs indicative of the CF diagnosis. 21, 22 Fat-soluble vitamin deficiencies and zinc deficiency are often present at the time of diagnosis by newborn screening; therefore, initiation of vitamin and mineral supplementation at diagnosis is imperative, followed by testing of serum levels of fat-soluble vitamins (A, 25-hydroxy D, E) and prothrombin time or protein induced in vitamin K absence 3-4 months following initiation of therapy. 13, 22, 23 The CFF newborn care guidelines provide guidance for newborn care, including vitamin and mineral supplementation. 13 Persons who have CF and PI are at risk for fat-soluble vitamin and certain mineral deficiencies despite appropriate use of PERT and therefore should receive specific daily vitamin supplementation. The supplementation is often above the upper limit as recommended by the dietary reference intakes of the National Academy of Sciences. There is evidence that pancreatic-sufficient persons require supplements of the fat-soluble vitamins. 24, 25 With exception of newborns, vitamin levels are assessed at the time of diagnosis. 26 For established patients, it is recommended that assessment of fat-soluble vitamins and, as indicated, minerals be done annually and following any change (usually 3 months) to usual nutrition therapy prior to prescription of vitamin or mineral supplements.
26 Table 3 provides the recommended schedule of assessment. 26 CF-specific vitamins contain fat-and water-soluble vitamins as well as zinc and reflect current vitamin research as it relates to CF. The content of these products is provided in Table 4 . Vitamin D recommendations have been published by the CFF, and Table 5 document provide step-by-step vitamin D dosing recommendations. 27 To enhance absorption, it is recommended that fat-soluble vitamins be taken with PERT and a fat-containing food or drink. The major minerals of concern in CF are sodium chloride and zinc. Individuals with CF lose excessive sodium chloride in their sweat; therefore, they require liberal amounts of salt in their diet to avoid salt depletion, particularly when they are sweating. For all full-term infants who have CF, the recommendation is 1/8 teaspoon of table salt daily, with an increase to 1/4 teaspoon at 6 months of age, if the infant is on the growth curve for weight. Premature infants or infants not on the growth curve for weight are dosed at 4 mEq/kg. 13 As the person with CF gets older and consumes a full diet, a liberal use of salt on food is recommended to meet sodium chloride needs. Those persons exposed to hot, humid conditions and those who are physically active require additional salt supplementation to avoid hyponatremic dehydration. One study recommends adding 1/8 salt to every 12 oz of standard sports drinks to stimulate thirst and drinking. 28 CF-specific multivitamins contain zinc. Additional zinc at 1 mg/kg up to 25 mg for 6 months is recommended if zinc deficiency is suspected. Zinc deficiency should be considered in the breast-fed baby not receiving a dietary source of zinc (meat) at 6 months of age and not growing adequately, for all patients demonstrating an unexplained decline in growth parameters or appetite, and/or those with prolonged diarrhea or uncontrolled malabsorption and retinol deficiency refractory to retinol supplementation.
Nutrition Support in CF
Many factors contribute to poor appetite, intake, and nutrition status in CF, such as abdominal symptoms (ie, constipation, delayed gastric emptying, and/or abdominal pain), increased work of breathing, as well as a variety of psychosocial and socioeconomic factors. 29 According to the 2012 CF Patient Registry, 43 .0% of CF patients use oral nutrition supplementation, while 11.4% require supplemental tube feeding. 4 Parenteral nutrition is rarely indicated in CF; it is mainly used only for patients who have persistent nonfunctioning bowel.
Nutrition interventions in patients with CF include behavioral approaches/interventions, oral supplementation, and enteral tube feedings. 30 Appetite stimulants are also commonly used.
Comprehensive nutrition assessment is recommended at CF patient clinic visits, including review of changes to and overall appetite of the patient. When decreased appetite is determined to be the primary cause for decreased nutrition status and intake, appetite stimulants should be considered. 29 Four commonly used appetite stimulants used in pediatric and adult CF patients are megestrol acetate (Megace), cyproheptadine hydrochloride (Periactin), dronabinol (Marinol), and mirtazapine (Remeron). 29, 31 Each of these 4 appetite stimulants have side effects, such as mild sedation or drowsiness, and some (eg, megestrol acetate) can cause adrenal suppression and hyperglycemia. 29, 31 Appetite stimulants can be used prior to use of more invasive nutrition support, such as tube feedings, but choice of product should be made cautiously and according to each patient.
According to a recent Cochrane review, oral protein energy supplements do not result in improved nutrition status, and these supplements should not be thought of as an essential part of nutrition care in CF. 32 However, the CFF recommends oral calorie supplements but cautions that they should be used in addition to usual dietary intake. 9 In general, any high-calorie supplement can be used for oral calorie supplementation for individuals with CF as long as they take PERT; specialized products for individuals with malabsorption or diabetes are not necessary. Some of the enzyme companies offer programs that provide free supplements; accredited CF centers will have information for patients and families about these programs. The CFF recommends enteral nutrition support for those with moderate to severe malnutrition, again in addition to usual dietary intake. 9 Enteral tube feeding is considered when dietary manipulation and oral supplements have failed. 33 The addition of enteral tube feeding has been associated with improved nutrition status, increased caloric intake, and delayed decline in pulmonary function. [33] [34] [35] Nasogastric and gastrostomy tube feedings are both well tolerated by CF patients and with few adverse side effects; however, most patients opt for gastrostomy tube feedings given the chronic need for nutrition support. 36 Individuals with CF and their caregivers, with guidance from CF care providers, must balance the potential benefits with the invasive nature of enteral feeding, the risks associated with it (eg, gastroesophageal reflux), and the costs associated with products and supplies. 35 Special considerations for enteral tube feeding are PERT and glycemic control. There is no consensus for use of PERT during tube feedings. However, general recommendations include dosing PERT based on fat grams provided by the enteral feeding formulation. 18 PERT administration options include enzymes taken by mouth, bolused via nectar-thick acidic fluid, crushed to powder and added to enteral formula, or dissolved in a sodium bicarbonate solution and added to enteral formula. 18, 36 Regarding glycemia, screening for CF-related diabetes (CFRD) by measuring mid-and immediate postfeeding plasma glucose levels is recommended for CF patients on continuous enteral feedings, at the time of gastrostomy feeding initiation and then monthly. 36 For patients who have CFRD or are diagnosed with CFRD after receiving tube feedings, insulin therapy should be used for management.
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CF-Related Diabetes
CFRD is the most common comorbidity associated with CF, and prevalence increases with age; up to 40%-50% of individuals with CF will have diabetes by the time that they are adults. [37] [38] [39] [40] CFRD is associated with worse pulmonary function, lower BMI, and increased mortality. [37] [38] [39] [40] [41] [42] In addition, patients with established CFRD are at equal risk of microvascular complications, such as retinopathy, nephropathy, neuropathy, and gastropathy, as are those with types 1 and 2 diabetes, particularly if fasting hyperglycemia is present. 43 In contrast to type 1 and type 2 diabetes, macrovascular disease does not appear to be a concern; there are no documented cases of deaths from atherosclerotic cardiac disease in patients with CFRD. 37 CFRD is a distinct clinical entity but shares characteristics from type 1 and type 2 diabetes. 39, 41, 43, 44 CFRD is mainly characterized by insulin insufficiency; however, patients also have fluctuating levels of insulin resistance related to chronic and acute infection, as well as intermittent use of steroids for some. 37, 43, 44 Many patients with CFRD do not have fasting hyperglycemia and have normal hemoglobin A1c levels at time 
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at NEW YORK UNIV MEDICAL CENTER on July 13, 2015 ncp.sagepub.com Downloaded from of diagnosis. Therefore, the U.S.-based CFF and the International Society of Pediatric and Adolescent Diabetes recommend annual screening for CFRD with an oral glucose tolerance test (OGTT; 1.75 g/kg of glucose; maximum, 75 g) starting at age 10. Hemoglobin A1c cannot be used alone as a screening mechanism, because it underestimates overall glycemic control and does not correlate well with OGTT results. 37, 43 Individuals with CF can have increased red blood cell turnover, making hemoglobin A1c spuriously low in these patients. 45 Ongoing diabetes self-management education from a multidisciplinary team of care providers familiar with CF as well as diabetes is recommended. 37, 43 CFRD is an insulin-insufficient state, making treatment with insulin the treatment of choice. 37, 43 Treatment with insulin, even at an early stage, can delay the decline in pulmonary function as well as improve BMI and overall nutrition status. 46 As with type 1 and type 2 diabetes, insulin treatment is individualized and meant to prevent large glycemic variability. An additional important treatment goal of insulin is to improve weight gain and BMI, both closely associated with pulmonary outcomes and mortality in individuals with CF. Generally, glycemic goals are similar to guidelines of the American Diabetes Association, including a target hemoglobin A1c <7%. 37 Individuals with CFRD are not encouraged to make dramatic changes to their diet (Table 6) . 37 Self-monitoring of blood glucose is encouraged at least 3 times daily, with quarterly A1c values measured for monitoring of CFRD. 37 In addition, annual screening for microvascular complications and annual lipid profile are recommended, after 5 years of diagnosis of CFRD.
37
Pregnancy
More women who have CF are becoming pregnant and delivering babies. The majority of papers describing pregnancy by women who have CF are retrospective chart reviews. Edenborough and Morton provided a summary of the works and care recommendations. 47 On the whole, most women do well during and following pregnancy, and pregnancy does not affect survival; however, there is heightened concern for women with less-than-optimal weight and/or CFRD and/or poor lung function prior to conception. Optimal nutrition (weight and BMI), before and during pregnancy, is essential for the well-being of the woman and her infant. The involvement of a dietitian, knowledgeable about the special needs of individuals with CF, through the pregnancy process improves overall nutrition outcome. 48 Vitamin supplementation is based on serum levels of fat-soluble vitamins. Normal vitamin A levels were reported in pregnant women who have CF and take CF-specific multivitamins. 49 As shown in Table 2 , the majority of vitamin A in the CF-specific multivitamins is in the form of beta-carotene, which is considered nontoxic. The CFF recommends blood glucose screening prior to pregnancy, for women who do not have CFRD and have not had a 2-hour OGTT in the previous 6 months. The test is repeated twice: during gestation weeks 12-16 and again during weeks 24-28. For women diagnosed with gestation diabetes, another 2-hour OGTT is recommended 6-12 weeks after delivery. Blood glucose levels are monitored per the CFF recommendations. The diet during pregnancy should contain sufficient calories to promote optimal weight gain; dietary restrictions are not appropriate to control blood sugars; and exogenous insulin is required if diabetes is present.
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Distal Intestinal Obstruction Syndrome
Patients with CF experience abdominal pain or discomfort regularly. Distal intestinal obstruction syndrome (DIOS) is a CF-specific complication that can cause significant abdominal pain, and it constitutes a medical emergency. While CF patients experience chronic and sometimes severe constipation, it is important to distinguish between DIOS and constipation. [50] [51] [52] DIOS is defined as an acute complete or incomplete fecal obstruction in the ileocecum. 50 Constipation, however, is defined as gradual fecal impaction of the total colon. 51 DIOS occurs primarily in patients with PI and is thought to be caused as a result of CFTR mutations resulting in accumulation of viscid fecal content. 53 Those who have had DIOS are at higher risk of subsequent episodes.
Complete DIOS includes complete intestinal obstruction with vomiting of bilious material and/or fecal loading in the right lower quadrant and with possible fluid levels in the small intestine on abdominal radiograph, fecal mass in the ileocecum, and abdominal pain with distention. 50 Incomplete or impending DIOS includes an ileocecal fecal mass and abdominal pain without complete obstruction and vomiting. 50, 51, 53 The collection of fecal material in the lower right quadrant in DIOS, as well as fairly acute onset of symptoms, distinguishes DIOS from constipation, as abdominal radiographs in constipation indicate accumulation of fecal material throughout the colon. 53 It is important to recognize and treat DIOS promptly to prevent need for surgical intervention. 53, 54 Incomplete DIOS often will respond to oral rehydration with stool softeners such as polyethylene glycol. 53 Treatment for complete DIOS should aim to correct systemic dehydration, then to thin fecal content causing blockage with oral laxatives, polyethylene glycol lavage, or Gastrograffin enema performed by an experienced radiologist. 50, 53, 54 Surgical intervention for complete DIOS is rarely needed with early aggressive treatment by a medical team familiar with the condition. Patients with CF are often encouraged to contact their CF clinical care team with symptoms of acute abdominal pain or discomfort. Recommended steps to prevent recurrent DIOS involves adherence to PERT, prevention of dehydration, and maintenance laxative therapy. 53 
Lung Transplant
While the life expectancy for individuals with CF continues to improve, respiratory failure continues to be the main cause of mortality for those afflicted with the disease. Lung transplantation offers those with end-stage lung disease a survival advantage and improved quality of life as compared with those who do not receive a transplant.
According to the CFF registry, >200 lung transplants were performed in individuals with CF in 2011, and about 2800 people with CF have received a lung transplant since 1990. 4 CF is the third major indication for lung transplantation, after emphysema and pulmonary fibrosis. 55 The majority of those transplanted receive a bilateral lung transplant; a small minority (<5%) require liver and lung transplantation. 56 Survival rates for lung transplant recipients regardless of indication are lower when compared with most other solid organ transplants; however, when compared with individuals receiving lung transplants for other indications, median survival is slightly better in those with CF: 7.5 years for all recipients and 10.4 years for those who survive the first year. Malnutrition is commonly seen in individuals with CF who have end-stage lung disease. The cause of malnutrition is multifactorial and often includes elevated resting energy expenditure, poor appetite, and frequent pulmonary exacerbations. Mean resting energy expenditure was 132% predicted in pediatric patients awaiting lung transplantation (majority with CF). 57 In addition, delayed gastric emptying is a common complication of end-stage disease in CF. 58 Efforts should be made to improve or at least preserve nutrition status while patients wait for transplantation, as adult patients with CF who have a BMI <18.5 kg/m 2 have a significantly higher risk of posttransplant mortality than do such patients with a normal or higher BMI. 59, 60 Additionally, depletion of fat-free mass was strongly associated with increased mortality while awaiting lung transplant and longer posttransplant intensive care unit stays. 61 Patients who do not have known CFRD should be screened preoperatively by OGTT if they have not had CFRD screening in the 6 months prior to listing for transplant. 37 Patients benefit from anticipatory guidance regarding the increased likelihood of developing temporary hyperglycemia necessitating insulin therapy during the immediate posttransplant period. In addition, they need to continue routine monitoring for CFRD, even after transplant-either on an annual basis or earlier with symptoms such as unexplained weight loss if they have not developed diabetes.
For most patients with CF, significant improvements in weight gain and BMI are noted after they recover from the immediate posttransplant period. 62, 63 There are no evidencebased guidelines to specify an optimal BMI for CF patients who are postlung transplant; the 2008 published guidelines with BMI goals of 23 for males and 22 for females are based on correlation to FEV 1 in pretransplant patients. 9 However, particularly since complications are quite common after transplant, it would seem prudent to recommend achieving and maintaining a normal BMI for age. Since energy expenditure may be lower and appetite significantly better, some patients may become overweight if they continue to follow the typical high-fat, high-calorie CF diet. Patients should be encouraged to return to their CF center for monitoring BMI trends, gastrointestinal symptoms/enzyme management, and secondary complications (eg, CFRD and gastrointestinal cancers), as well as for routine annual monitoring of fat-soluble vitamin levels. Increased vitamin A and E levels have been reported in CF patients after lung transplantation; hypervitaminosis A is particularly concerning, as toxicity can cause increased intracranial pressure, osteoporosis, and liver damage. 64 Standard CF vitamins may need to be discontinued since these products contain significant doses of vitamins A and E when compared with most general over-the-counter multivitamin products. Optimizing vitamin D levels may be particularly important in the posttransplant period, as low serum vitamin D levels are associated with increased rates of rejection and infection after lung transplantation. 65 
Summary
Significant strides have been made in the treatment and outcomes of CF. Clinicians play a critical role helping patients and their loved ones improve outcomes and quality of life with CF. As excitement builds for the potential to treat the disease at the cellular level, dedication to achieving and maintaining optimal nutrition status will help ensure that patients have the best chance at a long and relatively healthy life.
